N-(2-(5-fluoro-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ylamino)pyrimidin-4-ylamino)phenyl)methanesulfonamide | 1187341-81-6

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: N-(2-(5-fluoro-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ylamino)pyrimidin-4-ylamino)phenyl)methanesulfonamide
• 英文别名: N-[2-[[5-fluoro-2-[(3-oxo-4H-1,4-benzoxazin-7-yl)amino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide
• CAS: 1187341-81-6
• 化学式: C₁₉H₁₇FN₆O₄S
• 分子量: 444.446
• InChiKey: QCUCOQHOIWZVIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  143
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• [EN] SULFONAMIDES AS ZAP-70 INHIBITORS<br/>[FR] SULFONAMIDES EN TANT QU'INHIBITEURS DE ZAP-70
  申请人：CELLZOME LTD

  公开号：WO2009112490A1

  公开（公告）日：2009-09-17

  The invention relates to compounds of formula (I), wherein R1 to R9 and R4a have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of ZAP-70 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immuno logically- mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.

  本发明涉及公式（I）的化合物，其中R1至R9和R4a的含义如描述和权利要求中所述。所述化合物可用作ZAP-70的抑制剂，用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫学介导的疾病。本发明还涉及包括所述化合物的制药组合物，以及作为药物的使用和制备这种化合物。
• SULFONAMIDES AS ZAP-70 INHIBITORS
  申请人：Major Jeremy

  公开号：US20110098288A1

  公开（公告）日：2011-04-28

  The invention relates to compounds of formula (I) wherein R 1 to R 9 and R 4a have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of ZAP-70 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.

  本发明涉及式(I)的化合物，其中R1至R9和R4a的含义如所述和权利要求所述。所述化合物可用作ZAP-70的抑制剂，用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫介导疾病。本发明还涉及包括所述化合物的制药组合物，制备该化合物以及作为药物的用途。